Ansari A, Jayakumar M, Ahmad F, Venkatachalam T, Salameh L, Unnikannan H
Front Immunol. 2024; 15:1447625.
PMID: 39211048
PMC: 11357905.
DOI: 10.3389/fimmu.2024.1447625.
Hipp A, Bengsch B, Globig A
Discov Immunol. 2024; 2(1):kyad010.
PMID: 38567057
PMC: 10917240.
DOI: 10.1093/discim/kyad010.
van der Sluis T, van Haften F, van Duikeren S, Pardieck I, de Graaf J, Vleeshouwers W
J Immunother Cancer. 2023; 11(11).
PMID: 38030302
PMC: 10689370.
DOI: 10.1136/jitc-2023-007158.
Dadas O, Allen J, Buchan S, Kim J, Chan H, Mockridge C
Front Immunol. 2023; 14:1252274.
PMID: 37965342
PMC: 10641686.
DOI: 10.3389/fimmu.2023.1252274.
Damiani D, Tiribelli M
Biomedicines. 2023; 11(6).
PMID: 37371818
PMC: 10295997.
DOI: 10.3390/biomedicines11061724.
Antibody-based cancer immunotherapy by targeting regulatory T cells.
Li Q, Lu J, Li J, Zhang B, Wu Y, Ying T
Front Oncol. 2023; 13:1157345.
PMID: 37182149
PMC: 10174253.
DOI: 10.3389/fonc.2023.1157345.
Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies.
Charles J, Vrionis A, Mansur A, Mathias T, Shaikh J, Ciner A
Cancers (Basel). 2023; 15(9).
PMID: 37174089
PMC: 10177356.
DOI: 10.3390/cancers15092624.
Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs.
Bowakim-Anta N, Acolty V, Azouz A, Yagita H, Leo O, Goriely S
Front Immunol. 2023; 14:1023064.
PMID: 36993956
PMC: 10041113.
DOI: 10.3389/fimmu.2023.1023064.
Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information.
McDaniel M, Meibers H, Pasare C
Curr Opin Immunol. 2021; 73:25-33.
PMID: 34425435
PMC: 8648974.
DOI: 10.1016/j.coi.2021.07.013.
CD27 expression on Treg cells limits immune responses against tumors.
Muth S, Klaric A, Radsak M, Schild H, Probst H
J Mol Med (Berl). 2021; 100(3):439-449.
PMID: 34423375
PMC: 8843905.
DOI: 10.1007/s00109-021-02116-9.
Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W
Front Immunol. 2021; 12:670088.
PMID: 34122428
PMC: 8189155.
DOI: 10.3389/fimmu.2021.670088.
CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors.
Chen H, Wei F, Yin M, Zhao Q, Liu Z, Yu B
Cancer Immunol Immunother. 2021; 70(7):2059-2071.
PMID: 33439295
PMC: 10992360.
DOI: 10.1007/s00262-020-02838-8.
CD70 Inversely Regulates Regulatory T Cells and Invariant NKT Cells and Modulates Type 1 Diabetes in NOD Mice.
Ye C, Low B, Wiles M, Brusko T, Serreze D, Driver J
J Immunol. 2020; 205(7):1763-1777.
PMID: 32868408
PMC: 7787366.
DOI: 10.4049/jimmunol.2000148.
Past, Present, and Future of Anticancer Nanomedicine.
Kim K, Khang D
Int J Nanomedicine. 2020; 15:5719-5743.
PMID: 32821098
PMC: 7418170.
DOI: 10.2147/IJN.S254774.
Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei H, Hadjati J
Front Immunol. 2020; 11:702.
PMID: 32391013
PMC: 7188834.
DOI: 10.3389/fimmu.2020.00702.
Deoxynivalenol Affects Proliferation and Expression of Activation-Related Molecules in Major Porcine T-Cell Subsets.
Vatzia E, Pierron A, Saalmuller A, Mayer E, Gerner W
Toxins (Basel). 2019; 11(11).
PMID: 31694331
PMC: 6891462.
DOI: 10.3390/toxins11110644.
CD27 Promotes CD4 Effector T Cell Survival in Response to Tissue Self-Antigen.
Remedios K, Meyer L, Zirak B, Pauli M, Truong H, Boda D
J Immunol. 2019; 203(3):639-646.
PMID: 31209102
PMC: 6650327.
DOI: 10.4049/jimmunol.1900288.
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.
ONeill R, Cao X
Adv Cancer Res. 2019; 143:145-194.
PMID: 31202358
PMC: 7336166.
DOI: 10.1016/bs.acr.2019.03.003.
HLA-Class II Artificial Antigen Presenting Cells in CD4 T Cell-Based Immunotherapy.
Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B
Front Immunol. 2019; 10:1081.
PMID: 31156634
PMC: 6533590.
DOI: 10.3389/fimmu.2019.01081.
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.
Chretien S, Zerdes I, Bergh J, Matikas A, Foukakis T
Cancers (Basel). 2019; 11(5).
PMID: 31060337
PMC: 6562626.
DOI: 10.3390/cancers11050628.